phase II study of panitumumab with irinotecan as third-line treatment for advanced colorectal cancer patients

Phase 2

• Conditions: metastatic colorectal cancer

• Registration Number: JPRN-UMIN000005180
• Lead Sponsor: Yokohama city university

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-03-03
• Study Completion: 2015-01-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

Not provided

Exclusion Criteria

1) Advanced pleural effusion, ascites 2) CNS metastases 3) Infection 4) Diarrhea (watery stool) 5) Heart disease as a clinical problem 6) Severe complications (intestinal paralysis, intestinal obstruction, interstitial pneumonia or pulmonary fibrosis, it is difficult to control diabetes, heart failure, kidney failure, liver failure etc.) 7) Active double cancer 8) Severe mental disorder 9) Irinotecan, oxaliplatin, panitumumab history of hypersensitivity to 10) Treatment with atazanavir sulfate 11) Pregnant and lacting women 12) Severe drug allergy 13) Judged unfit to by doctors in this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response Rate:RR

Secondary Outcome Measures

Name	Time	Method
Safety Overall survival:OS Progression free survival:PFS Tumor shrinkage rate